N※N

Adaltis Inc.: Adaltis Appoints Vice-President Finance

  //business-finance.news-articles.net/content/200 .. inc-adaltis-appoints-vice-president-finance.html
  Published in Business and Finance on Friday, January 2nd 2009 at 4:50 GMT, Last Modified on 2009-01-02 04:51:23 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

MONTREAL, QUEBEC--(Marketwire - Jan. 02, 2009) - Adaltis Inc. (TSX:ADS), an international in vitro diagnostic (IVD) company, today announced the appointment of Ms. Ellen Cheung to the position of Vice-President, Finance, reporting to Mr. Pierre Larochelle, President and Chief Executive Officer of the Company.

Ms. Cheung graduated from the University of Western Ontario, in Canada, and has more than 20 years of experience in finance and management in Canada and China. She is based in Shanghai, China. Prior to joining Adaltis, Ms Cheung worked at Sanofi and at Dystar China Limited, a spin off company of BASF. She will replace Mr. Jacques Deforges, the Company's current Vice-president and Chief Financial Officer, who will leave the company to pursue other interests.

"This appointment is consistent with the Company's plan is to strengthen our China management team and create a China-based leading provider of in vitro diagnostic systems in emerging markets, with special focus on China", said Mr Larochelle, President and Chief Executive Officer of Adaltis. Mr. Larochelle also thanked Mr. Deforges for its contribution to the evolution of Adaltis over the last four years.

About Adaltis

Adaltis is an international in vitro diagnostic company with a mission to become a leading provider of in vitro diagnostic products in emerging markets, with a particular focus on China.

With the strategic advantage of its "state of the art" reagent manufacturing facility located in Shanghai, China, a complete IVD product offering targeting emerging markets, and a strong international sales and distribution platform, Adaltis is able to manufacture high-quality products in a low-cost GMP environment, in order to service existing markets in Europe, while providing a platform to penetrate the high-growth Chinese in vitro diagnostic market.

Adaltis is headquartered in Montreal, with offices in China, Italy and Mexico.

Caution Concerning Forward-Looking Statements

Although not an exhaustive list, we caution you that certain statements made in this press release are likely to be considered forward-looking statements, including in particular those related to the Company's plan.

Adaltis cautions that, by their nature, forward-looking statements involve risk and uncertainty and Adaltis' actual actions or results could differ materially from those expressed or implied in such forward-looking statements.

The forward-looking statements contained in this press release represent the expectations of Adaltis and its subsidiaries as at the date hereof and accordingly are subject to change after such date. However, Adaltis and its subsidiaries expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For additional information with respect to the risks and uncertainties and other factors that could cause the results or events predicted in these forward-looking statements to differ materially from actual results or events, please refer to the Annual Information Form of Adaltis filed with the Canadian securities commissions.